Trials / Not Yet Recruiting
Not Yet RecruitingNCT07524777
Ganoderma Spores Modulate the Gut-Brain Axis
Targeting the Gut-Brain Axis With Ganoderma Lucidum Spores Ameliorates Depression in Thyroid Cancer Patients: a Randomized, Double-blind, Placebo-controlled Trial
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Ling Zhiqiang · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to investigate whether Sporoderm-removed Ganoderma lucidum spore powder (RGLS) ameliorates depression in thyroid cancer patients through gut-brain axis modulation, and to elucidate the underlying microbial and metabolic mechanisms. This 3-month randomized, double-blind, placebo-controlled trial will enroll 300 postoperative papillary thyroid carcinoma patients with depressive symptoms (HAMD-24 ≥ 8). Participants will be randomly assigned(2 : 1) to receive RGLS (2 g/day) or matched placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Sporoderm-removed Ganoderma lucidum spore powder (RGLS) | From the first day after enrollment, subjects take RGLS orally at 4g/day for 3 months. |
| OTHER | Placebo | From the first day after enrollment, subjects take placebo orally at 4g/day for 3 months. |
Timeline
- Start date
- 2026-04-15
- Primary completion
- 2026-07-31
- Completion
- 2026-08-31
- First posted
- 2026-04-13
- Last updated
- 2026-04-13
Source: ClinicalTrials.gov record NCT07524777. Inclusion in this directory is not an endorsement.